Balazs_2021_Ideggyogy.Sz_74_379

Reference

Title : Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias - Balazs_2021_Ideggyogy.Sz_74_379
Author(s) : Balazs N , Bereczki D , Kovacs T
Ref : Ideggyogy Sz , 74 :379 , 2021
Abstract :

In aging societies, the morbidity and mortality of dementia is increasing at a significant rate, thereby imposing burden on healthcare, economy and the society as well. Patients' and caregivers' quality of life and life expectancy are greatly determined by the early diagnosis and the initiation of available symptomatic treatments. Cholinesterase inhibitors and memantine have been the cornerstones of Alzheimer's therapy for approximately two decades and over the years, more and more experience has been gained on their use in non-Alzheimer's dementias too. The aim of our work was to provide a comprehensive summary about the use of cholinesterase inhibitors and memantine for the treatment of Alzheimer's and non-Alzheimers's dementias.

PubMedSearch : Balazs_2021_Ideggyogy.Sz_74_379
PubMedID: 34856086

Related information

Citations formats

Balazs N, Bereczki D, Kovacs T (2021)
Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias
Ideggyogy Sz 74 :379

Balazs N, Bereczki D, Kovacs T (2021)
Ideggyogy Sz 74 :379